Ensysce Biosciences (ENSC) Receivables - Other (2021 - 2025)
Ensysce Biosciences (ENSC) has disclosed Receivables - Other for 5 consecutive years, with $4411.0 as the latest value for Q3 2025.
- On a quarterly basis, Receivables - Other fell 99.75% to $4411.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $4411.0, a 99.75% decrease, with the full-year FY2024 number at $124115.0, up 27.22% from a year prior.
- Receivables - Other was $4411.0 for Q3 2025 at Ensysce Biosciences, down from $1.2 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $1.8 million in Q3 2024 to a low of $4411.0 in Q3 2025.
- A 5-year average of $339190.7 and a median of $132464.0 in 2022 define the central range for Receivables - Other.
- Peak YoY movement for Receivables - Other: skyrocketed 1554.76% in 2024, then tumbled 99.75% in 2025.
- Ensysce Biosciences' Receivables - Other stood at $441721.0 in 2021, then crashed by 37.33% to $276821.0 in 2022, then plummeted by 64.76% to $97561.0 in 2023, then grew by 27.22% to $124115.0 in 2024, then crashed by 96.45% to $4411.0 in 2025.
- Per Business Quant, the three most recent readings for ENSC's Receivables - Other are $4411.0 (Q3 2025), $1.2 million (Q2 2025), and $22002.0 (Q1 2025).